Screening for major diseases in community pharmacies: A systematic review

International Journal of Pharmacy Practice

Volumn 21, Issue 6, 2013, Pages 349-361

  Ayorinde, Abimbola Adebukola ^a   Porteous, Terry ^a   Sharma, Pawana ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

community pharmacy; major diseases; screening

Indexed keywords

COMPARATIVE STUDY; DATA EXTRACTION; DATA SYNTHESIS; HOSPITAL DEPARTMENT; HUMAN; MEDICAL DEVICE; PATIENT EDUCATION; PATIENT INFORMATION; PATIENT SATISFACTION; PHARMACIST; PHARMACY; PRIORITY JOURNAL; QUALITY CONTROL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SCREENING; SOCIAL STATUS; SYSTEMATIC REVIEW;

COMMUNITY PHARMACY; MAJOR DISEASES; SCREENING;

COMMUNITY PHARMACY SERVICES; HUMANS; MASS SCREENING; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT SATISFACTION; QUALITY ASSURANCE, HEALTH CARE; SENSITIVITY AND SPECIFICITY;

EID: 84887490019     PISSN: 09617671     EISSN: 20427174     Source Type: Journal    
DOI: 10.1111/ijpp.12041     Document Type: Review

References (82)

1. World Health Organization. Global Status Report on Noncommunicable Diseases 2010. Geneva: World Health Organization, 2011.
2. World Health Organization. Gaining Health: the European Strategy for the Prevention and Control of Noncommunicable Diseases. Copenhagen: World Health Organization, 2006. http://www.euro.who.int/-data/assets/pdf-file/0008/76526/ E89306.pdf (accessed 14 July 2010).
3. UK National Screening Committee. What is screening? [online]. London: Crown copyright, undated. http://www.screening.nhs.uk/screening (accessed 14 July 2010).
4. Jepson R, et al. The determinants of screening uptake and interventions for increasing uptake: a systematic review. Health Technol Assess 2000; 4: i-vii, 1-133.
5. Bekker H, et al. Uptake of cystic fibrosis testing in primary care: supply push or demand pull? BMJ 1993; 306: 1584-1586. (Pubitemid 23164904)
6. Tambor ES, et al. Offering cystic fibrosis carrier screening to an HMO population: factors associated with utilization. Am J Hum Genet 1994; 55: 626-637. (Pubitemid 24298960)
7. Nichols S, et al. Randomised trial of compliance with screening for colorectal cancer. BMJ 1986; 293: 107-110. (Pubitemid 16096049)
8. Royal Pharmaceutical Society of Great Britain. Community Pharmacy: The Choice Is Yours. London: Royal Pharmaceutical Society of Great Britain, 1996.
9. National Health Service Grampian. When You Are Ill, Know Who to Turn to. Aberdeen: NHS Grampian, 2009. http://www.know-who-to-turn-to.com/pdf/21396- UnscheduledCare-WEB-1707.pdf (accessed 26 February 2010).
10. NHS Newcastle North and East Clinical Commissioning Group. Think Pharmacy First [online]. Newcastle-upon-Tyne: NHS Newcastle North and East Clinical Commissioning Group, 2012. http://www.newcastlenorthandeastccg.nhs.uk/make-the- most-of-your-nhs/think-pharmacy-first (accessed 14 July 2010; updated website accessed 30 April 2013).
11. The Pharmacy Guild of Australia. Ask your pharmacist [online]. Canberra: The Pharmacy Guild of Australia, undated. http://www.askyourpharmacist.com.au/ (accessed 2 November 2012).
12. Anderson C,. Health promotion in community pharmacy: the UK situation. Patient Educ Couns 2000; 39: 285-291. (Pubitemid 30004083)
13. Blenkinsopp A, et al. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Public Health Med 2003; 25: 144-153. (Pubitemid 36758777)
14. World Health Organization. Tackling Europe's Major Diseases: the Challenge and the Solutions. Geneva: World Health Organization, 2006.
15. Scottish Intercollegiate Guidelines Network. Annex C: critical appraisal-notes and checklists [online]. Edinburgh: Scottish Intercollegiate Guidelines Network, 2004-2013. http://www.sign.ac.uk/guidelines/fulltext/50/ annexc.html (accessed 1 March 2010).
16. Scottish Intercollegiate Guidelines Network. Key to evidence statements and grades of recommendations [online]. Edinburgh: Scottish Intercollegiate Guidelines Network, 2004-2013. http://www.sign.ac.uk/guidelines/fulltext/50/ annexb.html (accessed 26 February 2010).
17. Centre for Reviews and Dissemination. Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care. York: University of York, 2009.
18. Verhagen AP, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998; 51: 1235-1241. (Pubitemid 29009523)
19. Downs SH, Black N,. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998; 52: 377-384. (Pubitemid 28438523)
20. The Effective Practice Institute. The GATE notes: a generic appraisal tool for epidemiology [online]. Auckland: The University of Auckland, undated. http://user.meduni-graz.at/andrea.berghold/EBM/Gate-Notes.pdf (accessed 26 February 2010).
21. Elliott ME, et al. Pharmacy-based bone mass measurement to assess osteoporosis risk. Ann Pharmacother 2002; 36: 571-577. (Pubitemid 34270267)
22. Elliott ME, et al. Osteoporosis screening by community pharmacists: use of National Osteoporosis Foundation resources. J Am Pharm Assoc 2002; 42: 101-110; quiz 110-1.
23. Hare SK, Kraenow K,. Depression screenings: developing a model for use in a community pharmacy. J Am Pharm Assoc 2008; 48: 46-51.
24. Hersberger KE, et al. Sequential screening for diabetes-evaluation of a campaign in Swiss community pharmacies. Pharm World Sci 2006; 28: 171-179. (Pubitemid 44584052)
25. Castillo D, et al. COPD case finding by spirometry in high-risk customers of urban community pharmacies: a pilot study. Respir Med 2009; 103: 839-845.
26. Burton MA, et al. Respiratory function testing: the impact of respiratory scientists on the training and support of primary health care providers. Respirology 2004; 9: 260-264. (Pubitemid 38937402)
27. Crockett JA, et al. Patient responses to an integrated service, initiated by community pharmacists, for the prevention of osteoporosis. Int J Pharm Pract 2008; 16: 65-72. (Pubitemid 351453996)
28. Dettloff RW, Morse JA,. Demonstration of community pharmacy and managed care organization collaboration on cardiovascular disease risk factor identification using health risk appraisal. J Am Pharm Assoc 2009; 49: 220-222.
29. Donyai P, Van Den Berg M,. Coronary heart disease risk screening: the community pharmacy Healthy Heart Assessment Service. Pharm World Sci 2009; 31: 643-647.
30. Earle KA, et al. A physician-pharmacist model for the surveillance of blood pressure in the community: a feasibility study. J Hum Hypertens 2001; 15: 529-533. (Pubitemid 32780644)
31. Goode JV, et al. Regional osteoporosis screening, referral, and monitoring program in community pharmacies: findings from Project ImPACT: osteoporosis. JAPhA 2004; 44: 152-160.
32. Hersberger KE, et al. Screening for sleep disorders in community pharmacies-Evaluation of a campaign in Switzerland. J Clin Pharm Ther 2006; 31: 35-41.
33. Hourihan F, et al. Rural community pharmacy: a feasible site for a health promotion and screening service for cardiovascular risk factors. Aust J Rural Health 2003; 11: 28-35. (Pubitemid 37038451)
34. Knox ED, et al. Depression screening in a university campus pharmacy: a pilot project. JAPhA 2006; 46: 502-506. (Pubitemid 46037354)
35. Mangum SA, et al. Identifying at-risk patients through community pharmacy-based hypertension and stroke prevention screening projects. J Am Pharm Assoc 2003; 43: 50-55.
36. Marra CA, et al. Improving osteoarthritis detection in the community: pharmacist identification of new, diagnostically confirmed osteoarthritis. Arthritis Care Res 2007; 57: 1238-1244. (Pubitemid 47585470)
37. Snella KA, et al. Pharmacy- and community-based screenings for diabetes and cardiovascular conditions in high-risk individuals. J Am Pharm Assoc 2006; 46: 370-377. (Pubitemid 46037363)
38. Tran A, et al. The development of a sleep disorder screening program in Australian community pharmacies. Pharm World Sci 2009; 31: 473-480.
39. Bheekie A, et al. An assessment of asthmatic patients at four Western Cape community pharmacies. S Afr Med J 1998; 88: 262-266. (Pubitemid 28230195)
40. Clarke A,. Type 2 diabetes: awareness and screening in the community pharmacy setting. J Diabetes Nurs 2007; 11: 128-134.
41. Gardner SF, et al. Community pharmacy data bases to identify patients at high risk for hypercholesterolemia. Pharmacotherapy 1995; 15: 292-296.
42. Summers KM, Brock TP,. Impact of pharmacist-led community bone mineral density screenings. Ann Pharmacother 2005; 39: 243-248. (Pubitemid 40165212)
43. Madejski RM, Madejski TJ,. Cholesterol screening in a community pharmacy. J Am Pharm Assoc 1996; NS36: 243-248. (Pubitemid 26127568)
44. McKenney JM,. Evaluation of cholesterol screening in community pharmacies. Am Pharm 1993; NS33: 34-40.
45. Yuksel N, et al. Community pharmacist-initiated screening program for osteoporosis: randomized controlled trial. Osteoporos Int 2010; 21: 391-398.
46. Peterson GM, et al. Cardiovascular risk screening program in Australian community pharmacies. Pharm World Sci 2010; 32: 373-380.
47. Sookaneknun P, et al. Economic analysis of the diabetes and hypertension screening collaboration between community pharmacies and a Thai government primary care unit. Prim Care Diabetes 2010; 4: 155-164.
48. Olenak JL, Calpin M,. Establishing a cardiovascular health and wellness program in a community pharmacy: screening for metabolic syndrome. J Am Pharm Assoc 2010; 50: 32-36.
49. Winfrey C, et al. Pharmacist-initiated peripheral arterial disease screening program in a community pharmacy setting. J Am Pharm Assoc 2011; 51: 373-377.
50. Fuller JM, et al. Sleep disorders screening, sleep health awareness, and patient follow-up by community pharmacists in Australia. Patient Educ 2011; 83: 325-335.
51. Jiwa M, et al. Could community pharmacies offer an opportunity to improve outcomes for patients with bowel cancer? Q Prim Care 2011; 19: 105-108.
52. Taylor J, et al. A community pharmacy-based cardiovascular screening service: views of service users and the public. Int J Pharm Pract 2012; 20: 277-284.
53. Boyle TC, et al. Men's health initiative risk assessment study: effect of community pharmacy-based screening. J Am Pharm Assoc 2004; 44: 569-577.
54. Hampton A, et al. Measuring blood pressure in an inner city pharmacy: an attempt at coordination with general practice. Fam Pract 1990; 7: 52-55. (Pubitemid 20190302)
55. Mason HL, et al. Feasibility of cholesterol screening in a community pharmacy. Consult Pharm (USA) 1990; 5: 93-95.
56. Horgan JM, et al. Evaluation of a cardiovascular disease opportunistic risk assessment pilot ('Heart MOT' service) in community pharmacies. J Public Health 2010; 32: 110-116.
57. Pongwecharak J, Treeranurat T,. Screening for pre-hypertension and elevated cardiovascular risk factors in a Thai community pharmacy. Pharm World Sci 2010; 32: 329-333.
58. Barris Blundell D, et al. Screening for osteoporosis among post-menopausal women in community pharmacy. Pharm Pract 2006; 4: 95-101.
59. Cerulli J, Zeolla MM,. Impact and feasibility of a community pharmacy bone mineral density screening and education program. J Am Pharm Assoc 2004; 44: 161-167.
60. Chaiyakunapruk N, et al. Community pharmacy-based implementation and evaluation of an Osteoporosis Self-Assessment Tool for Asians. J Am Pharm Assoc 2006; 46: 391-396. (Pubitemid 46037366)
61. Law AV, Shapiro K,. Impact of a community pharmacist-directed clinic in improving screening and awareness of osteoporosis. J Eval Clin Pract 2005; 11: 247-255. (Pubitemid 40755686)
62. Liu Y, et al. Osteoporosis risk screening for women in a community pharmacy. JAPhA 2007; 47: 521-526.
63. MacLaughlin EJ, et al. Osteoporosis screening and education in community pharmacies using a team approach. Pharmacotherapy 2005; 25: 379-386.
64. Lata PF, et al. Acceptability of pharmacy-based bone density measurement by women and primary healthcare providers. Menopause 2002; 9: 449-455. (Pubitemid 36706340)
65. Naunton M, et al. Pharmacist-provided quantitative ultrasound screening for rural women at risk of osteoporosis. Ann Pharmacother 2006; 40: 38-44. (Pubitemid 43221472)
66. Farina RD, et al. Osteoporosis screening: is screening effective? Can it be done economically? Will people pay for it? US Pharmacist 1999; 24: 38-43.
67. Johnson JF, et al. Bone health screening, education, and referral project in northwest Iowa: creating a model for community pharmacies. J Am Pharm Assoc 2008; 48: 379-387.
68. Krass I, et al. Pharmacy diabetes care program: analysis of two screening methods for undiagnosed type 2 diabetes in Australian community pharmacy. Diabetes Res Clin Pract 2007; 75: 339-347. (Pubitemid 46074203)
69. King MJ, et al. Blood glucose measurement in the community pharmacy. Pharm J 1993; 250: 808-810.
70. Jiwa M, et al. Piloting and validating an innovation to triage patients presenting with cough to community pharmacies in Western Australia. Q Prim Care 2012; 20: 83-91.
71. Giles JT, et al. Results of a community pharmacy based breast cancer risk assessment and education program. Pharmacotherapy 2001; 21: 243-253. (Pubitemid 32119202)
72. Shepstone L, et al. A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Osteoporosis Int 2012; 23: 2507-2515.
73. Clark EM, et al. Randomized controlled trial of a primary care-based screening program to identify older women with prevalent osteoporotic vertebral fractures: cohort for skeletal health in Bristol and Avon (COSHIBA). J Bone Miner Res 2012; 27: 664-671.
74. Park P, et al. Screening for type 2 diabetes is feasible, acceptable, but associated with increased short-term anxiety: a randomised controlled trial in British general practice. BMC Public Health 2008; 8: 350.
75. Pommer AM, et al. Managing co-morbid depression and anxiety in primary care patients with asthma and/or chronic obstructive pulmonary disease: study protocol for a randomized controlled trial. Trials 2012; 13: 6.
76. Kida K, et al. Screening for suspected chronic obstructive pulmonary disease with an eleven-item pre-interview questionnaire (11-Q). Intern Med 2006; 45: 1201-1207. (Pubitemid 44848853)
77. Hewitson P, et al. Primary care endorsement letter and a patient leaflet to improve participation in colorectal cancer screening: results of a factorial randomised trial. Br J Cancer 2011; 105: 475-480.
78. Rasmussen SR, et al. Preventive health screenings and health consultations in primary care increase life expectancy without increasing costs. Scand J Public Health 2007; 35: 365-372. (Pubitemid 47386785)
79. Craig P, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 2008; 337: a1655.
80. Plowden KO, Miller JL,. Motivators of health seeking behavior in urban African-American men: an exploration of triggers and barriers. J Natl Black Nurses Assoc 2000; 11: 15-20.
81. UK National Screening Committee. Programme appraisal criteria [online]. London: Crown copyright, 2011. http://www.screening.nhs.uk/criteria (accessed 1 March 2010).
82. Anderson C, et al. Pharmacists' perceptions regarding their contribution to improving the public's health: a systematic review of the United Kingdom and international literature 1990-2001. Int J Pharm Pract 2003; 11: 111-120. (Pubitemid 36790934)